Clinical Trial Update: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase II multicentre randomized, double-blind trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of COMP360 in participants with recurren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• COMP360 (psilocybin)

Snippet

Sponsor: COMPASS Pathways | Conditions: Major Depressive Disorder | Phase 2 | Status: ACTIVE_NOT_RECRUITING